$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Forget Intuitive Surgical: This Stock Is the Next Millionaire Maker
01:15am, Friday, 05'th Jul 2024
Imagine this: you walk into a hospital for a procedure. You expect a long, traditional surgery with a lengthy recovery.
3 Top-Rated Gene Editing Stocks Actually Making Money
03:11pm, Wednesday, 03'rd Jul 2024
Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR
You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
10:02pm, Thursday, 27'th Jun 2024
With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the b
Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich
03:38pm, Thursday, 27'th Jun 2024
In 2024, the iShares Biotechnology ETF (NASDAQ: IBB ) is up just over 1.5%. If you're looking for steady, dividend-paying stocks, you can find a number of biotech stocks to buy from the holdings in t
You've Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.
02:21pm, Thursday, 27'th Jun 2024
Biotech stocks to buy now reflect a more dynamic shift in investor focus of late.Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Glob
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued.
08:00am, Thursday, 27'th Jun 2024
CRISPR Therapeutics is a gene-editing pioneer. Despite its landmark regulatory approvals with Casgevy, its shares have failed to excite the investment community.
3 Biotech Stocks That Could Make Your Grandchildren Rich
06:40am, Thursday, 27'th Jun 2024
In the world of investing, biotech stocks represent a unique blend of high risk and high reward. After a period of volatility in the broader markets in 2022 and 2023, biotech stocks are now drawing at
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
09:33pm, Wednesday, 26'th Jun 2024
Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body.
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
07:05pm, Wednesday, 26'th Jun 2024
CRISPR Therapeutics AG (CRSP) closed at $56.63 in the latest trading session, marking a +1.22% move from the prior day.
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
08:00am, Tuesday, 25'th Jun 2024
Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, the app
The Next Big Thing After AI? 3 Sleeper Stocks to Buy Before the Boom
10:54am, Monday, 24'th Jun 2024
Chasing the next trend thing after AI is easier said than done. It is also a pretty risky strategy.
Is Most-Watched Stock CRISPR Therapeutics AG (CRSP) Worth Betting on Now?
10:01am, Monday, 24'th Jun 2024
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
07:05pm, Thursday, 20'th Jun 2024
CRISPR Therapeutics AG (CRSP) reachead $59.60 at the closing of the latest trading day, reflecting a -1.6% change compared to its last close.
7 ‘FIRE' Stocks to Put You on the Path to Financial Freedom
01:44pm, Wednesday, 12'th Jun 2024
Because it's tied to one of the six leading causes of “finality,” stress represents a silent public health crisis. And few things cause heightened stress than dealing with you-know-what at work.
CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call Transcript
12:32pm, Tuesday, 11'th Jun 2024
CRISPR Therapeutics AG (NASDAQ:CRSP ) Company Conference Call June 11, 2024 9:20 AM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Salveen Richter - Goldma
Sign In
Buy CRSP